NCT04648254
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04648254
Title Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Qurient Co., Ltd.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Southern California Los Angeles California 90033 United States Details
Cedars-Sinai Medical Center Los Angeles California 90048 United States Details
Northwestern University Chicago Illinois 60611 United States Details
Atlantic Health System Hospital Morristown New Jersey 07960 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field